Dr. Johung on Prognosis of Patients With ALK-Rearranged NSCLC and Brain Metastases

Kimberly L. Johung, MD, PhD
Published: Friday, Oct 23, 2015



Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer (NSCLC) and brain metastases.

Approximately 5% of patients with NSCLC have ALK-rearranged disease, Johung explains. Researchers found that patients with the ALK mutation who develop brain metastases have an extended survival, with a median overall survival of 4 years.

This is in comparison to patients with NSCLC with other mutations aside from ALK and develop brain metastases, where the average prognosis is 6 months, Johung says.

<<< View more from the 2015 ASTRO Annual Meeting



Kimberly L. Johung, MD, PhD, assistant professor of Therapeutic Radiology, Gastrointestinal Cancer Program, Yale Cancer Center, discusses a study that examined the prognosis of patients with ALK-rearranged non–small cell lung cancer (NSCLC) and brain metastases.

Approximately 5% of patients with NSCLC have ALK-rearranged disease, Johung explains. Researchers found that patients with the ALK mutation who develop brain metastases have an extended survival, with a median overall survival of 4 years.

This is in comparison to patients with NSCLC with other mutations aside from ALK and develop brain metastases, where the average prognosis is 6 months, Johung says.

<<< View more from the 2015 ASTRO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x